*1. October 1959

Training

Study of Human Medicine at the Medical Faculty of the Rheinische-Friedrich-Wilhelms-Universität Bonn, 1979 – 1985.

Specialist training (neurology, psychotherapy) at the Clinics of Neurology and Psychiatry of the Medical Faculty of the Rheinische-Friedrich-Wilhelms-Universität Bonn, 1985 - 1993.

Lecturer and Supervisor for behavioral therapy since 2002.

since 2014	President of the Federal Institute for Drugs and Medical Devices (BfArM)
since 2013	Honorary Professor at the Medical Faculty of the Rheinische Friedrich-Wilhelms-Universität Bonn
2009 - 2014	Vice President of the Federal Institute for Drugs and Medical Devices (BfArM)
2005 - 2009	Head of Admission 4 at the Federal Institute for Drugs and Medical Devices (BfArM)
2000 – 2005	Head of Department Neurology / Psychiatry, Federal Institute for Drugs and Medical Devices, Bonn
1990 – 1991	Research stay at the Hospital of the University of Pennsylvania, Philadelphia, USA (PET and SPECT imaging of neurotransmitter receptors in neurodegenerative diseases)
1985 – 2000	Clinical-academic activity at neurolog. and psychiatr. University Hospitals

Current activities in the European network of regulatory authorities

Member of the European Medicines Agency’s Management Board (EMA MB), Chair of the Network Portfolio Advisory Group (NPAG), Member and currently Chair of the Heads of Medicines Agencies (HMA) Management Group, Co-chair of the EMA's Darwin EU Advisory Board.

Publications / other activities

Member of numerous societies, such as the German Society for Psychiatry, Psychotherapy and Neurology (DGPPN), German Society for Regulatory Affairs (DGRA), the European College of Neuropsychopharmacology (ECNP) and the International Society for CNS Clinical Trials and Methodology (ISCTM).

Prof. Dr. Broich is author and co-author of over 230 essays (original scientific papers, reviews, book contributions). Some of them are available at PubMed (National Library of Medicine) under the following link: Publications

Scientific focus

Clinical psychopharmacology, imaging of neurodegenerative diseases and other potential biomarkers and dementia, and clinical trial methodology.